Gordon Sanghera, Co-founder and CEO of Oxford Nanopore Technologies, shares insights on groundbreaking DNA and RNA sequencing technologies. He discusses the democratisation of genetic analysis and its potential to revolutionize healthcare, especially in cancer detection and personalized medicine. The conversation highlights recent developments showcased at the J.P. Morgan Healthcare Conference, emphasizing how these innovations can transform personal health strategies and contribute to more accurate treatments.